Search

Sudhanshu Agrawal Phones & Addresses

  • Irvine, CA
  • Orange, CA

Resumes

Resumes

Sudhanshu Agrawal Photo 1

Immune-Modulators/Cancer Drug Discovery/ Assay Development

View page
Position:
Specialist Div of Basic and Clinical Immunology/ Dept of Medicine at UC Irvine
Location:
Irvine, California
Industry:
Research
Work:
UC Irvine - Irvine , CA , USA since 2004
Specialist Div of Basic and Clinical Immunology/ Dept of Medicine

Emory Vaccine Centre / Emory Univeristy , Atlanta 2002 - 2004
Sr Research Project Coordinator

Immuno Designed Molecules , Paris, France 1999 - 2001
Scientist

Ranabaxy Lab Ltd , New Delhi 1994 - 1999
Scientist

BIBCOL (Under Dept .of Biotechnology, Govt. of India) 1989 - 1994
Manager Prodcution/ QC
Education:
MSU , Baroda , India
MS Biotech, Biotech
Certifications:
Qualification in Cytometry (ASCP), American College of Clinical Pathology
Sudhanshu Agrawal Photo 2

Sudhanshu Agrawal

View page
Sudhanshu Agrawal Photo 3

Intern At Kennametal Inc

View page
Position:
Engineering Intern at Kennametal, Student Vehicle Operator at The Ohio State University
Location:
Solon, Ohio
Industry:
Mechanical or Industrial Engineering
Work:
Kennametal - Cleveland/Akron, Ohio Area since Jun 2012
Engineering Intern

The Ohio State University - Columbus, Ohio Area since Jan 2012
Student Vehicle Operator
Education:
The Ohio State University 2009 - 2013

Publications

Us Patents

Methods For Identifying And Administering Agents That Bias The Immune Response Via Dendritic Cells

View page
US Patent:
20040259790, Dec 23, 2004
Filed:
Jan 30, 2004
Appl. No.:
10/769635
Inventors:
Bali Pulendran - Alpharetta GA, US
Sudhanshu Agrawal - Irvine CA, US
Stephanie Dillon - Atlanta GA, US
International Classification:
A61K038/17
US Classification:
514/012000, 424/093710
Abstract:
The invention provides a method of regulating a Th2 immune response which comprises contacting a cell with an amount of a molecule effective to modulate an ERK pathway and/or a c-FOS pathway in the cell so as a to regulate the TH2 immune response, which molecule is any of (a) an agonist of a TLR2 or a TLR2 variant; (b) an agonist of an intracellular pathway that is initiated by activation of a TLR2; (c) an agonist of an intracellular pathway that is initiated by activation of a receptor activated by SEA; (d) an antagonist of an intracellular pathway that opposes TLR2 signaling or activation; (e) an agonist of an ERK pathway; (f) an antagonist of a p38 pathway; (g) an antagonist of a JNK pathway; or (h) an agonist of the c-FOS pathway, or a molecule that induces c-Fos gene expression, c-Fos messenger RNA stability, c-Fos protein induction, c-Fos protein stability, or c-Fos protein phosphorylation.
Sudhanshu Agrawal from Irvine, CA, age ~60 Get Report